Gavin W. Roddy

ORCID: 0000-0002-8905-8588
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Glaucoma and retinal disorders
  • Retinal Diseases and Treatments
  • Corneal surgery and disorders
  • Retinal Development and Disorders
  • Ocular Surface and Contact Lens
  • Ophthalmology and Eye Disorders
  • Corneal Surgery and Treatments
  • Photoreceptor and optogenetics research
  • Retinal Imaging and Analysis
  • Retinal and Optic Conditions
  • Cerebral Venous Sinus Thrombosis
  • Intraocular Surgery and Lenses
  • Artificial Intelligence in Healthcare and Education
  • Advanced Glycation End Products research
  • Facial Rejuvenation and Surgery Techniques
  • Tissue Engineering and Regenerative Medicine
  • Ocular Infections and Treatments
  • Retinal and Macular Surgery
  • Ocular Oncology and Treatments
  • Retinopathy of Prematurity Studies
  • Mesenchymal stem cell research
  • Neonatal Respiratory Health Research
  • Mitochondrial Function and Pathology
  • Neurobiology and Insect Physiology Research
  • Heat shock proteins research

Mayo Clinic in Arizona
2014-2025

Mayo Clinic
2016-2024

Mayo Clinic in Florida
2019-2023

WinnMed
2017-2022

Foundation for Medical Research
2022

National Eye Institute
2022

Ophthalmology Associates (United States)
2021

American Glaucoma Society
2020-2021

Baylor Scott & White Health
2018

St. Luke's Hospital
2015

Abstract Previous reports demonstrated that the deleterious effects of chemical injury to cornea were ameliorated by local or systemic administration adult stem/progenitor cells from bone marrow referred as mesenchymal stem stromal (MSCs). However, mechanisms for beneficial MSCs on injured not clarified. Herein, we human (hMSCs) effective in reducing corneal opacity and inflammation without engraftment after either intraperitoneal (i.p.) intravenous (i.v.) following rat cornea. A...

10.1002/stem.708 article EN Stem Cells 2011-08-11

Previous reports demonstrated that adult stem/progenitor cells from bone marrow (multipotent mesenchymal stem cells; MSCs) can repair injured tissues with little evidence of engraftment or differentiation. In exploring this phenomenon, our group has recently discovered the therapeutic benefits MSCs are in part explained by being activated signals to express an anti-inflammatory protein TNF-α–stimulated gene/protein 6 (TSG-6). Therefore, we elected test hypothesis TSG-6 would have effects...

10.1073/pnas.1012451107 article EN Proceedings of the National Academy of Sciences 2010-09-13

Mesenchymal stem/progenitor cells (MSCs) were reported to enhance the survival of cellular and organ transplants. However, their mode action was not established. We here used a mouse model corneal allotransplantation demonstrated that peri-transplant intravenous (i.v.) infusion human MSCs (hMSCs) decreased early surgically induced inflammation reduced activation antigen-presenting (APCs) in cornea draining lymph nodes (DLNs). Subsequently, immune rejection decreased, allograft prolonged....

10.1038/mt.2012.165 article EN cc-by-nc-nd Molecular Therapy 2012-08-28

ObjectiveTo determine the appropriateness of ophthalmology recommendations from an online chat-based artificial intelligence model to questions.Patients and MethodsCross-sectional qualitative study April 1, 2023, 30, 2023. A total 192 questions were generated spanning all ophthalmic subspecialties. Each question was posed a large language (LLM) 3 times. The responses graded by appropriate subspecialists as appropriate, inappropriate, or unreliable in 2 grading contexts. first context if...

10.1016/j.mcpdig.2024.01.003 article EN cc-by-nc-nd Mayo Clinic Proceedings Digital Health 2024-02-15

Specialized ophthalmology terminology limits comprehension for nonophthalmology clinicians and professionals, hindering interdisciplinary communication patient care. The clinical implementation of large language models (LLMs) into practice has to date been relatively unexplored. To evaluate LLM-generated plain summaries (PLSs) integrated standard notes (SONs) in improving diagnostic understanding, satisfaction, clarity. Randomized quality improvement study conducted from February 1, 2024,...

10.1001/jamaophthalmol.2025.0351 article EN JAMA Ophthalmology 2025-04-03

Limited population-based data as well proposed mechanisms of retinal ganglion cell (RGC) loss suggest autoimmune disease may be a risk factor for glaucoma, the leading cause irreversible blindness worldwide. Though intraocular pressure (IOP) is glaucoma onset and progression, subset referred to normal tension (NTG) more likely associated with IOP-independent RGC injury including those an inflammatory or immune nature. This retrospective case-control study enrolled 277 patients NTG same...

10.1186/s12886-025-03893-4 article EN cc-by-nc-nd BMC Ophthalmology 2025-02-11

Oxidative stress and photoreceptor apoptosis are prominent features of many forms retinal degeneration (RD) for which there currently no effective therapies. We previously observed that mesenchymal stem/stromal cells reduce by being activated to secrete stanniocalcin-1 (STC-1), a multifunctional protein reduces oxidative upregulating mitochondrial uncoupling protein-2 (UCP-2). Therefore, we tested the hypothesis intravitreal injection STC-1 can rescue photoreceptors. first in rhodopsin...

10.1038/mt.2011.308 article EN cc-by-nc-nd Molecular Therapy 2012-01-31

Précis: Multiple systemic vascular-associated conditions including hypertension and hypotension, diabetes mellitus, migraine headache, peripheral vascular disease, Raynaud syndrome, anemia were associated with low-tension glaucoma. Purpose: The purpose of this study was to identify risk factors Patients Methods: A retrospective case-control design employed patients seen at the Mayo Clinic Department Ophthalmology between 2005 2015 glaucoma an age-matched sex-matched control group, each...

10.1097/ijg.0000000000001964 article EN cc-by Journal of Glaucoma 2021-11-02

Introduction: Metabolic syndrome is a disorder characterized by constellation of findings including truncal obesity, elevated blood pressure, abnormal cholesterol levels, and high glucose. Recent evidence suggests that metabolic may be associated with increased risk age-related macular degeneration (AMD) other eye diseases. Recently, C57BL/6J wild-type mice fed "fast food" diet consisting fat, cholesterol, fructose-supplemented water showed unique systemic pathology consistent nonalcoholic...

10.1080/02713683.2019.1694156 article EN Current Eye Research 2019-11-18

Purpose/Aim Abnormal activation of signaling pathways related to angiogenesis, inflammation, and oxidative stress has been implicated in the pathophysiology retinopathy prematurity (ROP), a leading cause blindness pre-term infants. Therapies for ROP include laser anti-vascular endothelial growth factor agents. However, these therapies have side effects, even with adequate treatment, visual acuity can be impaired. Novel therapeutic options are needed. Stanniocalcin-1 (STC-1) is...

10.1080/02713683.2019.1645184 article EN Current Eye Research 2019-07-17

Trabeculectomy surgery is a commonly performed procedure for treatment of glaucoma. While the goal to lower intraocular pressure, over-filtration may cause hypotony with ocular structural changes and vision loss. A 53-year-old woman primary open-angle glaucoma was referred our service further evaluation. The patient previously underwent trabeculectomy 9 years prior found have cataract maculopathy in right eye. Treatment options included alone, bleb revision or combined extraction revision....

10.1016/j.ajoc.2024.102003 article EN cc-by-nc-nd American Journal of Ophthalmology Case Reports 2024-02-10

Purpose: To identify downstream signaling molecules through which intraocular pressure (IOP) is lowered following treatment with the prostaglandin analog latanoprost. Methods: Total RNA and protein isolated from primary human Schlemm's canal cells (n = 3) treated latanoprost (free acid; 100 nM) were processed for quantitative PCR Western blot analysis. IOP was evaluated in stanniocalcin-1 (STC-1−/−) wild-type mice or Rho kinase inhibitor Y27632. Human anterior segment pairs 8) recombinant...

10.1167/iovs.16-21004 article EN cc-by-nc-nd Investigative Ophthalmology & Visual Science 2017-05-24

Intraocular pressure is currently the only known reliable, modifiable risk factor for development and progression of glaucoma. Other factors glaucoma include increasing age, myopia, decreased central corneal thickness, low hysteresis (CH) measurements. Photoablative keratorefractive surgery including laser assisted in situ keratomileusis (LASIK) has become a common way to treat refractive error, with over 25 million procedures performed United States alone. Though myopic LASIK been...

10.1097/ijg.0000000000002395 article EN Journal of Glaucoma 2024-06-14

Abstract Parathyroid hormone (PTH; 10 −7 to −15 M) decreased terminal chondrogenesis in the avian sterna. During first half of an 8‐day culture, 100 nM PTH (1–34) significantly increased sternal length and downregulated deposition type X collagen its mRNA expression. However, it remains unclear how cartilaginous growth. In this study, we examined growth by both cell proliferation analysis cyclin d1 mRNA. Types II, IX, collagens were quantified through real‐time RT‐PCR, while Ki‐67 was used...

10.1002/ar.20416 article EN The Anatomical Record 2007-01-31

For patients with glaucoma, metabolic syndrome was associated higher intraocular pressure and greater central corneal thickness. Patients were more likely to have ocular hypertension.The purpose of this study determine whether glaucomatous optic neuropathy, also known as hypertension are occur in syndrome.Patients Olmsted County, MN, identified having based on diagnosis codes, laboratory values, and/or medication use meet 3 or the 5 standard criteria for diagnosing syndrome: systemic...

10.1097/ijg.0000000000001968 article EN Journal of Glaucoma 2021-12-02

Purpose: To evaluate the effect of ATP-sensitive potassium channel openers cromakalim prodrug 1 (CKLP1) and diazoxide on IOP in three independent mouse models ocular hypertension. Methods: Baseline was measured TGFβ2 overexpression, steroid-induced, iris dispersion (DBA/2J) hypertension models, followed by once daily eyedrop administration with CKLP1 (5 mM) or mM). The conscious animals a handheld rebound tonometer. Aqueous humor dynamics were assessed constant perfusion method. Effect...

10.1167/iovs.63.2.15 article EN cc-by-nc-nd Investigative Ophthalmology & Visual Science 2022-02-07

Purpose To determine whether metabolic syndrome (MetS) is a risk factor for various forms of optic neuropathy including non-arteritic anterior ischaemic (NAION). Methods This population-based analysis identified patients ≥40 years age in Olmsted County, Minnesota, USA using the Rochester Epidemiology Project 2005–2018. Patients with MetS were if three or more five standard criteria diagnosing present: systemic hypertension, hyperglycaemia, hypertriglyceridaemia, reduced high-density...

10.1136/bmjophth-2022-001111 article EN cc-by-nc BMJ Open Ophthalmology 2022-10-01

Prostaglandin F2 alpha (PGF2α) analogues such as latanoprost are common first-line intraocular pressure (IOP) lowering medications. However, their clinical use is limited in some patient populations due to minimal or no IOP response side effects. In searching for a more targeted approach reduction, our lab recently identified Stanniocalcin-1 (STC-1) molecule that was required latanoprost-mediated reduction and also acted stand-alone agent. order determine whether STC-1 were equivalent and/or...

10.1371/journal.pone.0232591 article EN cc-by PLoS ONE 2020-05-04

Precis: Diplopia was present in ~20% of patients with Ahmed FP7 (FP7) or Baerveldt 350 (B350), compared 5% to 6% those 250 (B250) controls, suggesting risk diplopia should be included preoperative counseling. Purpose: The purpose this study examine the prevalence and strabismus B250, B350, glaucoma drainage devices (GDD). Materials Methods: In cohort study, 18 years above who had received, would receiving, a GDD, medically treated controls were consecutively enrolled from August 8, 2017,...

10.1097/ijg.0000000000001886 article EN Journal of Glaucoma 2021-05-27
Coming Soon ...